BiotechTube

Satavaptan + placebo

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyponatremia

Conditions

Hyponatremia, Inappropriate ADH Syndrome

Trial Timeline

Jul 1, 2008 → Dec 1, 2008

NCT ID
NCT00728091

About Satavaptan + placebo

Satavaptan + placebo is a phase 3 stage product being developed by Sanofi for Hyponatremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00728091. Target conditions include Hyponatremia, Inappropriate ADH Syndrome.

What happened to similar drugs?

1 of 7 similar drugs in Hyponatremia were approved

Approved (1) Terminated (3) Active (4)
✅ConivaptanAstellas PharmaApproved
🔄YM087Astellas PharmaPhase 3
❌ConivaptanAstellas PharmaPhase 3
🔄lixivaptan + PlaceboBiogenPhase 3
❌LixivaptanBiogenPhase 3
🔄lixivaptan + placeboBiogenPhase 3
🔄Lixivaptan + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00728091Phase 3Terminated
NCT00366795Phase 3Terminated
NCT00358878Phase 3Completed
NCT00359437Phase 3Terminated

Competing Products

9 competing products in Hyponatremia

See all competitors
ProductCompanyStageHype Score
YM087Astellas PharmaPhase 3
40
ConivaptanAstellas PharmaApproved
35
ConivaptanAstellas PharmaPhase 3
32
Tolvaptan + PlaceboJiangsu Hengrui MedicinePhase 2/3
34
lixivaptan + PlaceboBiogenPhase 3
37
LixivaptanBiogenPhase 3
29
lixivaptan + placeboBiogenPhase 3
37
Lixivaptan + PlaceboBiogenPhase 3
37
PEG-SD + PEG-ELSBausch HealthPre-clinical
20